Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,624.70
-17.4917-1.06%
Number of Gainers:1
Number of Losers:6
Number of Flat:- -
PE:- -
High:1,643.38
Open:1,643.38
Low:1,613.30
Close:1,642.78
Volume:11.61M
Turnover:1.13B
Market Cap:1.69T
Float Cap:1.63T

Loading ...

Novo Nordisk Advances DKK 15 Billion Share Buyback Programme Through Late August 2026

TIPRANKS
·
1 hour ago

Political and General News Events from August 31

Reuters
·
1 hour ago

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
2 hours ago

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
2 hours ago

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
3 hours ago

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
3 hours ago

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
3 hours ago

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
3 hours ago

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
3 hours ago

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
3 hours ago

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
4 hours ago

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
4 hours ago

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
4 hours ago

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
4 hours ago

Amgen Says Repatha Cuts Death Risk 20% in High-Risk Patients

MT Newswires Live
·
4 hours ago

Amgen Repatha reduces risk of death in high-risk adults for first heart attack

TIPRANKS
·
5 hours ago

Amgen's Repatha® Reduces Risk of Death in Patients at High Risk for a First Heart Attack or Stroke

THOMSON REUTERS
·
7 hours ago

Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29